References
- 1. Fateen E, Abdallah ZY. Twenty-five years of biochemical diagnosis of Gaucher disease: the Egyptian experience. Heliyon, 2019, 5(10):e02574.
- 2. Ruchlemer R MM, Zimran A. Gaucher disease, myelodys-plastic syndrome and ICUS. Blood Cells Mol Dis., 2020, 80(102373).
- 3. Pernick, N. Bone marrow – nonneoplastic systemic disorders. Gaucher disease. Pathology Outlines, 2019.
- 4. Beutler E, Demina A, Gelbart T. Glucocerebrosidase mutations in Gaucher disease. Mol Med, 1994, 1(1):82-92.
- 5. Beutler E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc Natl Acad Sci U S A, 1993, 90(12):5384-90.
- 6. Beutler E, Gelbart T. Gaucher disease mutations in non-Jewish patients. Br J Haematol, 1993., 85(2):401-5.
- 7. Riboldi G, Di Fonzo AB. Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 2019, 8(4), 364. doi: 10.3390/cells8040364.
- 8. Anheim M, Elbaz A, Lesage S et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology, 2012, 78(6):417-20.
- 9. McNeill A, Duran R, Proukakis C et al. Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord, 2012, 27(4):526-32.
- 10. Bultron G, Kacena K, Pearson D et al. The risk of Parkinson‘s disease in type 1 Gaucher disease. J Inherit Metab Dis, 2010. 33(2):167-73.